126 related articles for article (PubMed ID: 31735626)
1. Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors.
Mazrooei P; Kron KJ; Zhu Y; Zhou S; Grillo G; Mehdi T; Ahmed M; Severson TM; Guilhamon P; Armstrong NS; Huang V; Yamaguchi TN; Fraser M; van der Kwast T; Boutros PC; He HH; Bergman AM; Bristow RG; Zwart W; Lupien M
Cancer Cell; 2019 Dec; 36(6):674-689.e6. PubMed ID: 31735626
[TBL] [Abstract][Full Text] [Related]
2. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.
Zhou S; Hawley JR; Soares F; Grillo G; Teng M; Madani Tonekaboni SA; Hua JT; Kron KJ; Mazrooei P; Ahmed M; Arlidge C; Yun HY; Livingstone J; Huang V; Yamaguchi TN; Espiritu SMG; Zhu Y; Severson TM; Murison A; Cameron S; Zwart W; van der Kwast T; Pugh TJ; Fraser M; Boutros PC; Bristow RG; He HH; Lupien M
Nat Commun; 2020 Jan; 11(1):441. PubMed ID: 31974375
[TBL] [Abstract][Full Text] [Related]
3. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis.
Pomerantz MM; Li F; Takeda DY; Lenci R; Chonkar A; Chabot M; Cejas P; Vazquez F; Cook J; Shivdasani RA; Bowden M; Lis R; Hahn WC; Kantoff PW; Brown M; Loda M; Long HW; Freedman ML
Nat Genet; 2015 Nov; 47(11):1346-51. PubMed ID: 26457646
[TBL] [Abstract][Full Text] [Related]
4. Deciphering essential cistromes using genome-wide CRISPR screens.
Fei T; Li W; Peng J; Xiao T; Chen CH; Wu A; Huang J; Zang C; Liu XS; Brown M
Proc Natl Acad Sci U S A; 2019 Dec; 116(50):25186-25195. PubMed ID: 31727847
[TBL] [Abstract][Full Text] [Related]
5. Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.
Stelloo S; Nevedomskaya E; Kim Y; Hoekman L; Bleijerveld OB; Mirza T; Wessels LFA; van Weerden WM; Altelaar AFM; Bergman AM; Zwart W
Oncogene; 2018 Jan; 37(3):313-322. PubMed ID: 28925401
[TBL] [Abstract][Full Text] [Related]
6. Mutations in Noncoding
El Ghamrasni S; Quevedo R; Hawley J; Mazrooei P; Hanna Y; Cirlan I; Zhu H; Bruce JP; Oldfield LE; Yang SYC; Guilhamon P; Reimand J; Cescon DW; Done SJ; Lupien M; Pugh TJ
Mol Cancer Res; 2022 Jan; 20(1):102-113. PubMed ID: 34556523
[TBL] [Abstract][Full Text] [Related]
7. TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer.
Kron KJ; Murison A; Zhou S; Huang V; Yamaguchi TN; Shiah YJ; Fraser M; van der Kwast T; Boutros PC; Bristow RG; Lupien M
Nat Genet; 2017 Sep; 49(9):1336-1345. PubMed ID: 28783165
[TBL] [Abstract][Full Text] [Related]
8. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
9. FOXA1 regulates ribosomal RNA transcription in prostate cancer.
Jia T; Liu C; Guo P; Xu Y; Wang W; Liu X; Wang S; Zhang X; Guo H
Prostate; 2024 Jul; 84(10):967-976. PubMed ID: 38632701
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer reactivates developmental epigenomic programs during metastatic progression.
Pomerantz MM; Qiu X; Zhu Y; Takeda DY; Pan W; Baca SC; Gusev A; Korthauer KD; Severson TM; Ha G; Viswanathan SR; Seo JH; Nguyen HM; Zhang B; Pasaniuc B; Giambartolomei C; Alaiwi SA; Bell CA; O'Connor EP; Chabot MS; Stillman DR; Lis R; Font-Tello A; Li L; Cejas P; Bergman AM; Sanders J; van der Poel HG; Gayther SA; Lawrenson K; Fonseca MAS; Reddy J; Corona RI; Martovetsky G; Egan B; Choueiri T; Ellis L; Garraway IP; Lee GM; Corey E; Long HW; Zwart W; Freedman ML
Nat Genet; 2020 Aug; 52(8):790-799. PubMed ID: 32690948
[TBL] [Abstract][Full Text] [Related]
11. FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression.
Zhao JC; Fong KW; Jin HJ; Yang YA; Kim J; Yu J
Oncogene; 2016 Aug; 35(33):4335-44. PubMed ID: 26751772
[TBL] [Abstract][Full Text] [Related]
12. Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer.
Tam KJ; Liu L; Hsing M; Dalal K; Thaper D; McConeghy B; Yenki P; Bhasin S; Peacock JW; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
Sci Rep; 2024 Mar; 14(1):7082. PubMed ID: 38528115
[TBL] [Abstract][Full Text] [Related]
13. Parallel Reporter Assays Identify Altered Regulatory Role of rs684232 in Leading to Prostate Cancer Predisposition.
Ren N; Liu Q; Yan L; Huang Q
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445492
[TBL] [Abstract][Full Text] [Related]
14. A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding.
Huang Q; Whitington T; Gao P; Lindberg JF; Yang Y; Sun J; Väisänen MR; Szulkin R; Annala M; Yan J; Egevad LA; Zhang K; Lin R; Jolma A; Nykter M; Manninen A; Wiklund F; Vaarala MH; Visakorpi T; Xu J; Taipale J; Wei GH
Nat Genet; 2014 Feb; 46(2):126-35. PubMed ID: 24390282
[TBL] [Abstract][Full Text] [Related]
15. Cell-lineage specificity and role of AP-1 in the prostate fibroblast androgen receptor cistrome.
Leach DA; Panagopoulos V; Nash C; Bevan C; Thomson AA; Selth LA; Buchanan G
Mol Cell Endocrinol; 2017 Jan; 439():261-272. PubMed ID: 27634452
[TBL] [Abstract][Full Text] [Related]
16. Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence.
Sunkel B; Wu D; Chen Z; Wang CM; Liu X; Ye Z; Horning AM; Liu J; Mahalingam D; Lopez-Nicora H; Lin CL; Goodfellow PJ; Clinton SK; Jin VX; Chen CL; Huang TH; Wang Q
Nucleic Acids Res; 2016 May; 44(9):4105-22. PubMed ID: 26743006
[TBL] [Abstract][Full Text] [Related]
17. An NKX3.1 binding site polymorphism in the l-plastin promoter leads to differential gene expression in human prostate cancer.
Chen C; Cai Q; He W; Li Z; Zhou F; Liu Z; Zhong G; Chen X; Zhao Y; Dong W; Huang J; Zheng J; Lin T
Int J Cancer; 2016 Jan; 138(1):74-86. PubMed ID: 26148677
[TBL] [Abstract][Full Text] [Related]
18. A FOXA1-binding enhancer regulates Hoxb13 expression in the prostate gland.
McMullin RP; Dobi A; Mutton LN; Orosz A; Maheshwari S; Shashikant CS; Bieberich CJ
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):98-103. PubMed ID: 20018680
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome.
Malinen M; Niskanen EA; Kaikkonen MU; Palvimo JJ
Nucleic Acids Res; 2017 Jan; 45(2):619-630. PubMed ID: 27672034
[TBL] [Abstract][Full Text] [Related]
20. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells.
Sahu B; Laakso M; Pihlajamaa P; Ovaska K; Sinielnikov I; Hautaniemi S; Jänne OA
Cancer Res; 2013 Mar; 73(5):1570-80. PubMed ID: 23269278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]